These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 22934599)

  • 41. Dengue virus envelope domain III immunization elicits predominantly cross-reactive, poorly neutralizing antibodies localized to the AB loop: implications for dengue vaccine design.
    Li XQ; Qiu LW; Chen Y; Wen K; Cai JP; Chen J; Pan YX; Li J; Hu DM; Huang YF; Liu LD; Ding XX; Guo YH; Che XY
    J Gen Virol; 2013 Oct; 94(Pt 10):2191-2201. PubMed ID: 23851440
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Retrospective serological study on sequential dengue virus serotypes 1 to 4 epidemics in Tainan City, Taiwan, 1994 to 2000.
    Chang SF; Huang JH; Chen LK; Su CL; Liao TL; Chien LJ; Lin TH; Su CJ; Shu PY
    J Microbiol Immunol Infect; 2008 Oct; 41(5):377-85. PubMed ID: 19122918
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice.
    Ramasamy V; Arora U; Shukla R; Poddar A; Shanmugam RK; White LJ; Mattocks MM; Raut R; Perween A; Tyagi P; de Silva AM; Bhaumik SK; Kaja MK; Villinger F; Ahmed R; Johnston RE; Swaminathan S; Khanna N
    PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006191. PubMed ID: 29309412
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
    Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
    Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Human monoclonal antibodies to neutralize all dengue virus serotypes using lymphocytes from patients at acute phase of the secondary infection.
    Setthapramote C; Sasaki T; Puiprom O; Limkittikul K; Pitaksajjakul P; Pipattanaboon C; Sasayama M; Leuangwutiwong P; Phumratanaprapin W; Chamnachanan S; Kusolsuk T; Jittmittraphap A; Asai A; Arias JF; Hirai I; Kuhara M; Okuno Y; Kurosu T; Ramasoota P; Ikuta K
    Biochem Biophys Res Commun; 2012 Jul; 423(4):867-72. PubMed ID: 22713454
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Monoclonal antibodies that bind to common epitopes on the dengue virus type 2 nonstructural-1 and envelope glycoproteins display weak neutralizing activity and differentiated responses to virulent strains: implications for pathogenesis and vaccines.
    Falconar AK
    Clin Vaccine Immunol; 2008 Mar; 15(3):549-61. PubMed ID: 18160621
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characterization of the Type-Specific and Cross-Reactive B-Cell Responses Elicited by a Live-Attenuated Tetravalent Dengue Vaccine.
    Michlmayr D; Andrade P; Nascimento EJM; Parker A; Narvekar P; Dean HJ; Harris E
    J Infect Dis; 2021 Feb; 223(2):247-257. PubMed ID: 32572472
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High performance dengue virus antigen-based serotyping-NS1-ELISA (plus): A simple alternative approach to identify dengue virus serotypes in acute dengue specimens.
    Prommool T; Sethanant P; Phaenthaisong N; Tangthawornchaikul N; Songjaeng A; Avirutnan P; Mairiang D; Luangaram P; Srisawat C; Kasinrerk W; Vasanawathana S; Sriruksa K; Limpitikul W; Malasit P; Puttikhunt C
    PLoS Negl Trop Dis; 2021 Feb; 15(2):e0009065. PubMed ID: 33635874
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Direct and indirect interactions in the recognition between a cross-neutralizing antibody and the four serotypes of dengue virus.
    Lisova O; Belkadi L; Bedouelle H
    J Mol Recognit; 2014 Apr; 27(4):205-14. PubMed ID: 24591178
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dengue Virus prM-Specific Human Monoclonal Antibodies with Virus Replication-Enhancing Properties Recognize a Single Immunodominant Antigenic Site.
    Smith SA; Nivarthi UK; de Alwis R; Kose N; Sapparapu G; Bombardi R; Kahle KM; Pfaff JM; Lieberman S; Doranz BJ; de Silva AM; Crowe JE
    J Virol; 2016 Jan; 90(2):780-9. PubMed ID: 26512092
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Therapeutic Effects of Monoclonal Antibody against Dengue Virus NS1 in a STAT1 Knockout Mouse Model of Dengue Infection.
    Wan SW; Chen PW; Chen CY; Lai YC; Chu YT; Hung CY; Lee H; Wu HF; Chuang YC; Lin J; Chang CP; Wang S; Liu CC; Ho TS; Lin CF; Lee CK; Wu-Hsieh BA; Anderson R; Yeh TM; Lin YS
    J Immunol; 2017 Oct; 199(8):2834-2844. PubMed ID: 28904127
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunodomination of Serotype-Specific CD4+ T-Cell Epitopes Contributed to the Biased Immune Responses Induced by a Tetravalent Measles-Vectored Dengue Vaccine.
    Lin TH; Chen HW; Hsiao YJ; Yan JY; Chiang CY; Chen MY; Hu HM; Wu SH; Pan CH
    Front Immunol; 2020; 11():546. PubMed ID: 32300346
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III.
    Hu D; Zhu Z; Li S; Deng Y; Wu Y; Zhang N; Puri V; Wang C; Zou P; Lei C; Tian X; Wang Y; Zhao Q; Li W; Prabakaran P; Feng Y; Cardosa J; Qin C; Zhou X; Dimitrov DS; Ying T
    PLoS Pathog; 2019 Jun; 15(6):e1007836. PubMed ID: 31242272
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Japanese encephalitis virus prM-E antigen immunization conferred protection against challenge by four different serotypes of Dengue viruses in mice.
    Gao N; Li J; Sheng Z; Chen H; Fan D; Wang P; An J
    Appl Microbiol Biotechnol; 2019 Jun; 103(12):4977-4986. PubMed ID: 31037380
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo.
    Williams KL; Wahala WM; Orozco S; de Silva AM; Harris E
    Virology; 2012 Jul; 429(1):12-20. PubMed ID: 22537810
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Detection of Dengue Virus-Specific IgM and IgG Antibodies through Peptide Sequences of Envelope and NS1 Proteins for Serological Identification.
    Nagar PK; Savargaonkar D; Anvikar AR
    J Immunol Res; 2020; 2020():1820325. PubMed ID: 32832567
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dominant cross-reactive B cell response during secondary acute dengue virus infection in humans.
    Zompi S; Montoya M; Pohl MO; Balmaseda A; Harris E
    PLoS Negl Trop Dis; 2012; 6(3):e1568. PubMed ID: 22448292
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation and analysis of dengue virus enhancing and neutralizing activities using simple high-throughput assays.
    Li XQ; Chen J; Huang YF; Ding XX; Liu LD; Qiu LW; Pan YX; Deng YQ; Hu DM; Di B; Qin CF; Che XY
    Appl Microbiol Biotechnol; 2013 Jul; 97(14):6503-11. PubMed ID: 23760532
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Development and characterization of serotype-specific monoclonal antibodies against Dengue virus NS1].
    Liu Y; Zhang Y; Wei Y; Jia X; Chen Q; Liu W; Yang L
    Sheng Wu Gong Cheng Xue Bao; 2020 Oct; 36(10):2206-2215. PubMed ID: 33169584
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dengue and Zika Virus Domain III-Flagellin Fusion and Glycan-Masking E Antigen for Prime-Boost Immunization.
    Lin HH; Yang SP; Tsai MJ; Lin GC; Wu HC; Wu SC
    Theranostics; 2019; 9(16):4811-4826. PubMed ID: 31367259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.